Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial

Publication | Open Access

DOI Full Paper Access

635

Citations

References

2017

Year

Véronique Dièras, David Miles, Sunil Verma, Mark D. Pegram, Manfred Welslau, José Baselga, Ian E. Krop, Kim T. Blackwell, Silke Hoersch, Jin Xu,

The Lancet Oncology

Breast OncologyOncologyDescriptive AnalysisBreast CancerCancer TreatmentVersus CapecitabineMedicineRadiation Oncology